Anti-Alpha-Spectrin, N-terminal [9.5.21] Antibody

This mouse IgG monoclonal antibody was generated against human red blood cell a-spectrin N terminal 1/3rd and is specific for human red blood cell a-spectrin N terminal 1/3rd of the protein.

Highlights:

  • Reacts with human red blood cell a-spectrin N terminal 1/3rd  of the protein
  • Recommended for Western Blot applications

Spectrin is a cytoskeletal protein that lines the intracellular side of the plasma membrane in eukaryotic cells along with actin. Spectrin plays a role in cell shape control, arrangement of transmembrane proteins, and organelle positioning. Specifically, Alpha-spectrin is a tetramer and mutations in alpha-spectrin can result in a variety of hereditary red blood cell disorders (e.g. spherocytic hemolytic anemia including elliptocytosis type 2, pyropoikilocytosis).

From the laboratories of David W. Speicher, PhD, The Wistar Institute.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
EWI028
Anti-Alpha-Spectrin, N-terminal [9.5.21] Antibody
50uL In stock
Regular Price:$355.00
On Sale:
Specifications

Product Type: Antibody
Alternative Name(s): Erythroid alpha-spectrin,Spectrin alpha chain, erythrocytic 1
Antigen: Human Red Blood Cell a-Spectrin N terminal 1/3rd of the protein
Accession ID: P02549
Molecular Weight: 280 kDa
Isotype: IgG
Clonality: Monoclonal
Clone Name: 9.5.21
Reactivity: Human
Immunogen: Human Red Blood Cell a-Spectrin N terminal 1/3rd of the protein
Species Immunized: Mouse
Purification Method: Affinity Purified
Tested Applications: Western Blot (1:250,000; 30sec exposure)
Storage: -20C
Shipped: Cold packs

Data

Western Blot

Lane 1, Human Melanoma (1205 LU); Lane 2, Human Ovarian Cancer (RMG1); Lane 3, Human Ovarian Cancer (OV90); Lane 4, Human Red Cell Membrane. Gel loads: Lanes 1-3, 25mg; Lane 4, 5mg. Antibody dilution: 1:250,000, 30sec exposure.

Provider
From the laboratories of David W. Speicher, PhD, The Wistar Institute.
References

If you publish research with this product, please let us know so we can cite your paper.

Loading...